Senior VP of Global Research & Chief Scientific Officer, Amgen
Search every verified Howard Chang interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In a 2013 interview, Howard Chang discussed the TRINOVA-1 trial, which he described as part of a series of studies Amgen had been conducting in patients with ovarian cancer. He stated that the trial was investigating an agent called trebanib, a peptibody designed to block angiopoietin 1 and 2, thereby blocking angiogenesis. Chang noted that TRINOVA-1 was a randomized study in recurrent and relapsed ovarian cancer, using weekly paclitaxel as the backbone chemotherapy, with patients receiving either trebanib or placebo.
“The TRINOVA studies are the studies that Amgen has been involved in for the past several years; it is a study being conducted in patients with ovarian cancer.”
“We are investigating an agent called trebanib, which is a peptibody designed to block angiopoietin 1 and 2, thereby blocking angiogenesis.”
“There are three studies all together; the first one, TRINOVA‑1, is a study being conducted in recurrent and relapsed ovarian cancer with a backbone chemotherapy of weekly paclitaxel.”
“It is a randomized study and patients are being randomized to receive either trebanib or placebo.”
David D. Chang, MD, PhD, head of global oncology development at Amgen, discusses the design of the TRINOVA-1 trial in ...
Sign in to search the full transcript archive, filter by topic, and access every quote from Howard Chang.